(Total Views: 546)
Posted On: 01/01/2021 1:21:02 PM
Post# of 153283
Ok, fair enough. I agree there are definitely a lot of question marks around GvHD...
What I find interesting is this: wouldn't switching from a blinded randomized placebo-controlled design to an open-label design under which all enrollees receive leronlimab - and esp. the FDA agreeing to that change - suggest that it would have been unethical to continue giving placebo, probably or possibly because there were signs of efficacy observed?
What I find interesting is this: wouldn't switching from a blinded randomized placebo-controlled design to an open-label design under which all enrollees receive leronlimab - and esp. the FDA agreeing to that change - suggest that it would have been unethical to continue giving placebo, probably or possibly because there were signs of efficacy observed?
(1)
(0)Scroll down for more posts ▼
